Clinical trial
STA-5326 in Crohn's Disease Patients
NCT00088062 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00088062 |
|---|---|
| Title | STA-5326 in Crohn's Disease Patients |
| Official title | A Phase I/IIa Trial of STA-5326 in Crohn's Disease Patients With CDAI Scores of 220-450 |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | STA-5326 |
| Enrollment | 48 |
| Start date | Feb 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jul 21, 2004 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: